Dermira (DERM) Receiving Favorable News Coverage, Study Shows

News coverage about Dermira (NASDAQ:DERM) has trended positive on Tuesday, according to AlphaOne Sentiment. The research group, a service of Accern, identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dermira earned a coverage optimism score of 0.26 on AlphaOne’s scale. AlphaOne also gave news headlines about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the immediate future.

These are some of the headlines that may have impacted Alpha One’s scoring:

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Dermira (NASDAQ DERM) traded up 0.27% during midday trading on Tuesday, hitting $29.77. The stock had a trading volume of 133,716 shares. The stock’s market capitalization is $1.24 billion. The company’s 50 day moving average price is $28.71 and its 200-day moving average price is $31.30. Dermira has a 52 week low of $25.63 and a 52 week high of $38.75.

Several equities analysts have weighed in on the company. Raymond James Financial, Inc. assumed coverage on Dermira in a research note on Thursday, March 16th. They issued an “underperform” rating on the stock. Citigroup Inc. assumed coverage on Dermira in a research note on Wednesday, March 15th. They issued an “underperform” rating on the stock. They noted that the move was a valuation call. Mizuho assumed coverage on Dermira in a research note on Thursday, March 30th. They issued a “buy” rating and a $42.00 target price on the stock. Guggenheim reissued a “positive” rating and issued a $40.00 target price on shares of Dermira in a research note on Thursday, March 2nd. Finally, BidaskClub raised Dermira from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Dermira presently has a consensus rating of “Hold” and an average target price of $42.00.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2655829/dermira-derm-receiving-favorable-news-coverage-study-shows.html.

In other news, insider Eugene A. Bauer sold 2,500 shares of the business’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $33.53, for a total value of $83,825.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Thomas G. Wiggans sold 8,000 shares of the business’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $33.49, for a total value of $267,920.00. Following the completion of the transaction, the chief executive officer now directly owns 14,468 shares in the company, valued at $484,533.32. The disclosure for this sale can be found here. Insiders sold a total of 18,615 shares of company stock worth $586,139 over the last three months. 17.30% of the stock is owned by company insiders.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:DERM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.